Evidence map›Paper›PMID 34927113›Full record

ArticleMed (New York, N.Y.)2022

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection.

Arjun Puranik, Patrick J Lenehan, Eli Silvert, Michiel J M Niesen, Juan Corchado-Garcia, John C O'Horo, Abinash Virk, Melanie D Swift, Joel E Gordon, Leigh Lewis Speicher and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Med (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Arjun Puraniknference, Cambridge, MA 02139, USA.
Patrick J Lenehannference, Cambridge, MA 02139, USA.
Eli Silvertnference, Cambridge, MA 02139, USA.
Michiel J M Niesennference, Cambridge, MA 02139, USA.
Juan Corchado-Garcianference, Cambridge, MA 02139, USA.
John C O'HoroDivision of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.
Abinash VirkDivision of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.
Melanie D SwiftDivision of Aerospace, Occupational and Preventive Medicine, Mayo Clinic, Rochester, MN 55902, USA.
Joel E GordonDepartment of Family Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA.
Leigh Lewis SpeicherDivision of General Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
Holly L GeyerDivision of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
Walter KremersDivision of Biomedical Statistics, Mayo Clinic, Rochester, MN 55902, USA.
John HalamkaMayo Clinic Platform, Mayo Clinic, Rochester, MN 55902, USA.
Andrew D BadleyDivision of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.
A J Venkatakrishnannference, Cambridge, MA 02139, USA.
Venky Soundararajannference, Cambridge, MA 02139, USA.
Nference (United States) · USMayo Clinic in Arizona · USMayo Clinic · USMayo Clinic in Florida · USMayo Clinic Health System · USMayo Clinic Hospital · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Prime shock and kill for HIV erradicationR01AI110173 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2014 to 2024
$6.9M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.R01AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2015 to 2019
$2.5M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistenceR56AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2021 to 2021
$607k
NIAID NIH HHS R01 AI110173NIAID NIH HHS R01 AI120698NIAID NIH HHS R56 AI120698NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

backgroundmRNA coronavirus disease 2019 (COVID-19) vaccines are safe and effective, but increasing reports of breakthrough infections highlight the need to vigilantly monitor and compare the effectiveness of these vaccines.

methodsWe retrospectively compared protection against symptomatic infection conferred by mRNA-1273 and BNT162b2 at Mayo Clinic sites from December 2020 to September 2021. We used a test-negative case-control design to estimate vaccine effectiveness (VE) and to compare the odds of symptomatic infection after full vaccination with mRNA-1273 versus BNT162b2, while adjusting for age, sex, race, ethnicity, geography, comorbidities, and calendar time of vaccination and testing.

findingsBoth vaccines were highly effective over the study duration (VE

conclusionsBoth mRNA-1273 and BNT162b2 strongly protect against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is imperative to continue monitoring and comparing available vaccines over time and with respect to emerging variants to inform public and global health decisions.

fundingThis study was funded by nference.

Indexed as

COVID-192019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19 VaccinesHumansRetrospective StudiesSARS-CoV-22019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19 VaccinesBNT162b2comparative effectivenessCOVID-19mRNA-1273mRNA vaccinesSARS-CoV-2

Identifiers

PMID34927113
PMCPMC8664708
OpenAlexW4200235080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.